Just one day after AstraZeneca and FibroGen received a knock-back from a US Food and Drug Administration advisory panel on their oral anemia treatment roxadustat, GlaxoSmithKline has unveiled data which could help it overtake its rivals.
An FDA expert committee voted almost unanimously against the approval of roxadustat on 15 July, coming out 13 to 1...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?